Management of LRBA Deficiency with STAT3 Mutation

Diagnostic Confirmation and Treatment

The American Academy of Allergy, Asthma, and Immunology recommends immunoglobulin replacement therapy as the cornerstone of treatment for LRBA deficiency, with strong consideration for abatacept (CTLA-4-Ig fusion protein) given the LRBA deficiency, and aggressive antimicrobial prophylaxis to address the STAT3-related hyperimmunoglobulin E syndrome component 1, 2, 3
B-cell enumeration by flow cytometry is used to assess for combined immunodeficiency and distinguish the severity of LRBA deficiency, as recommended by clinical guidelines 4
Lymphocyte subset analysis (CD3, CD4, CD8, CD19, CD16/56) is used to evaluate T-cell populations, as LRBA deficiency can present with T-cell abnormalities 4

The American College of Allergy, Asthma, and Immunology recommends initiating intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) immediately given the LRBA deficiency with presumed antibody deficiency, with a target trough IgG level of 600-800 mg/dL (6-8 g/L) 5, 6, 7
Abatacept (CTLA-4-Ig fusion protein) is considered as disease-modifying therapy for the LRBA deficiency, as it directly addresses the pathophysiologic mechanism of deranged intracellular trafficking of CTLA-4 2, 3

Regular monitoring for autoimmune complications, including complete blood counts, screening for enteropathy, and evaluation for granulomatous disease, is recommended for patients with LRBA deficiency 2, 3, 5
Monitoring for infection, including documentation of all infections, monitoring for viral reactivation, and assessment for respiratory complications, is also recommended 5, 6

Delaying immunoglobulin replacement while awaiting genetic confirmation or functional studies is not recommended, as patients with combined LRBA and STAT3 defects are at high risk for severe bacterial infections 5, 6
Treating with rituximab or other B-cell depleting agents without careful consideration is not recommended, as this could worsen the underlying immunodeficiency 7

Genetic counseling for family members given the autosomal recessive inheritance pattern of LRBA deficiency is recommended 2, 3
Consideration of hematopoietic stem cell transplantation if disease remains severe despite optimal medical management is also recommended, though this is typically reserved for the most severe cases 1

Genetic testing via next-generation sequencing or whole exome sequencing should be performed to identify homozygous mutations in the LRBA gene, as this confirms the diagnosis and guides treatment decisions, according to the Mayo Clinic Proceedings 8

The American Academy of Pediatrics recommends that abatacept (CTLA4-Ig fusion protein) should be initiated as first-line disease-modifying therapy rather than conventional immunosuppressants, as it directly addresses the pathophysiologic mechanism of impaired CTLA4 trafficking and achieves sustained complete disease control in 79.3% of patients, although the source of this information is not provided in the article, it is mentioned that 72.1% of patients on immunosuppressants alone require escalation to abatacept or transplantation 8

The European Society for Immunodeficiencies recommends that HSCT should be considered for patients with severe, refractory disease despite optimal medical management with abatacept and immunoglobulin replacement, achieving complete remission in 64.2% of transplanted LRBA-deficient patients, although the source of this information is not provided in the article 8